News coverage about Cumberland Pharmaceuticals (NASDAQ:CPIX) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.8572178591927 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) traded up 4.26% during trading on Friday, hitting $7.10. The stock had a trading volume of 25,602 shares. The stock has a 50 day moving average of $6.86 and a 200 day moving average of $6.53. The firm’s market cap is $112.86 million. Cumberland Pharmaceuticals has a 52-week low of $4.46 and a 52-week high of $7.49.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter. The firm had revenue of $8.67 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 0.13% and a negative net margin of 19.57%. On average, equities analysts anticipate that Cumberland Pharmaceuticals will post $0.09 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Cumberland Pharmaceuticals (CPIX) Receives Daily Media Impact Score of 0.16” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Stock Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.